HAIKOU, August 24. /TASS/. An innovative American drug Lumakras (also known as Sotorasib) for lung cancer and other types of cancer may soon become available at Hainan Lecheng Medical Cluster, reported www.jiemian.com. 

According to the news outlet, an agreement was signed between Hainan Chengmei Medicine and Baiji shenzhou.

Lumakras is designed for advanced or metastatic non-small cell lung cancer. It is effective against tumors with KRAS G12C mutation, which occurs in 30% of lung, colon, pancreas and thyroid cancers.

Lumakras is developed by Amgen, a multinational biopharmaceutical company based in state of California (US). In May 2021, the drug was approved for use by the US Food and Drug Administration (FDA), and in June by the UAE regulators.

Lecheng International Medical Tourism Pilot Zone in Hainan's Boao was established in 2013. Its area reaches 20 sq. km, there are clinics practicing traditional Chinese and Western medicine on its territory. This cluster attracts highly qualified specialists from China and abroad, and also cooperates with leading foreign medical institutions to provide top-notch services. By 2025, the Chinese authorities intend to bring Lecheng to a global level in the field of medical technology and equipment. In particular, within the framework of this project, it is planned to create an advanced clinical center and a base for conducting research.